JP-2022532402-A5 -

Dates

Publication Date

20230522

Application Date

20200514

Description

[Invention 1001]A method for treating EGFR-mutant non-small cell lung cancer (NSCLC) in a patient, comprising the step of administering a CD70-targeted molecule to the patient.[Invention 1002]A method for treating epithelial-mesenchymal transition (EMT)-positive NSCLC in a patient, comprising the step of administering a CD70-targeted molecule to the patient.[Invention 1003]The method of the present invention 1001 or 1002, wherein the patient has been determined to have EGFR variant NSCLC.[Invention 1004]A method according to any one of the present invention 1001 to 1003, wherein NSCLC includes lung adenocarcinoma.[Invention 1005]A method according to any of 1001 to 1004 of the present invention, wherein the patient is a non-smoker.[Invention 1006]A method according to any one of the present invention 1001 to 1005, wherein the EGFR variant includes an activating mutation.[Invention 1007]The method of the present invention 1006, wherein the activating mutation includes L858R or a deletion in exon 19.[Invention 1008]A method according to any one of the present invention 1001 to 1007, wherein the EGFR mutation comprises a class I, II, or III EGFR mutation.[Invention 1009]A method according to any of items 1001 to 1008 of the present invention, wherein the patient has not been tested for CD70 expression in cancer cells.[Invention 1010]A method according to any one of items 1001 to 1008 of the present invention, wherein the patient has been determined to have CD70-expressing cancer cells.[Invention 1011]A method according to any of items 1001 to 1010 of the present invention, wherein the patient has previously received treatment for NSCLC.[Invention 1012]The method of the present invention 1011, wherein it is determined that the patient has acquired resistance to the previous treatment.[Invention 1013]The method of the present invention 1011 or 1012, wherein the prior treatment comprises EGFR tyrosine kinase inhibitor (TKI) therapy, and the therapy comprises one or more EGFR TKIs.[Invention 1014]A method according to any of invention 1011 to 1013, wherein the previous treatment includes monotherapy with an EGFR TKI.[Invention 1015]A method according to any one of invention 1011 to 1013, wherein the prior treatment includes a combination of at least two EGFR TKIs.[Invention 1016]A method according to any one of items 1011 to 1015 of the present invention, wherein it is determined that a patient is experiencing systemic disease progression while receiving continuous EGFR TKI therapy.[Invention 1017]A method according to any one of the present invention 1013 to 1016, wherein the EGFR TKI therapy comprises one or more of gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, and brigatinib.[Invention 1018]Any method of the present invention 1001 to 1017, further comprising the implementation of further therapies.[Invention 1019]The method of the present invention 1018, wherein further therapy includes chemotherapy, radiation, surgery, TKI therapy, or immunotherapy.[Invention 1020]The method of the present invention 1018 or 1019, wherein the further therapy comprises one or more of durvalumab, atezolizumab, pembrolizumab, nivolumab, necitumumab, and bevacizumab.[Invention 1021]Any method of the present invention 1018 to 1020, wherein the further therapy comprises one or more of carboplatin, pemetrexed, nab-paclitaxel, photofrin, cisplatin, docetaxel, gemcitabine, paclitaxel, and vinorelbine.[Invention 1022]A method of any of the invention 1018 to 1021, wherein the further therapy comprises one or more of alectinib, lorlatinib, and ceritinib.[Invention 1023]Any method of the present invention 1018 to 1022, wherein the further therapy comprises one or more of gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, and brigatinib.[Invention 1024]The method of the present invention 1023, wherein the further therapy includes osimertinib.[Invention 1025]Any method of the present invention 1001 to 1022, further comprising the implementation of adjuvant therapy and/or neoadjuvant therapy.[Invention 1026]A method according to any of items 1001 to 1025 of the present invention, wherein the patient has been determined to be an ALK variant.[Invention 1027]A method according to any of items 1001 to 1025 of the present invention, wherein the patient has been determined not to be an ALK variant.[Invention 1028]A method according to any one of the present invention 1001 to 1027, wherein the CD70 target-directed molecule comprises an anti-CD70 antibody or a CD70-binding fragment thereof.[Invention 1029]Further therapy involves the method of the present invention 1028, comprising a secondary antibody linked to a toxic molecule.[Invention 1030]The method of the present invention 1029, wherein a secondary antibody and a toxic molecule are linked through a cleavable linker.[Invention 1031]A method according to any one of the present invention 1028 to 1030, wherein the antibody is a humanized antibody or a chimeric antibody.[Invention